AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25881090 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics administered orally for 6 days preoperatively and 10 days postoperatively.
Number of subjects: 150
Study 25881090 — intervention group
Group type: COMPARATOR
Intervention: Control group received placebo orally for 6 days preoperatively and 10 days postoperatively.
Number of subjects: 150
Study 25881090 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics group.
Number of subjects: 150
Study 25881090 — intervention group
Group type: COMPARATOR
Intervention: Control group.
Number of subjects: 150
Study 24078623 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrelease planning for improving HIV medication adherence
Number of subjects: 162
Study 24078623 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrelease planning for reducing sexual and injection drug-related transmission risk
Number of subjects: 162
Study 21978943 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse oximetry
Number of subjects: 90
Study 21978943 — intervention group
Group type: COMPARATOR
Intervention: Fetal electrocardiography (STAN® technology)
Number of subjects: 90
Study 18816009 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week manualized guided self-help
Number of subjects: 102
Study 18816009 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 102
Study 16484823 — intervention group
Group type: EXPERIMENTAL
Intervention: PenV 1.5 million IU thrice daily for 20 days
Number of subjects: 102
Study 16484823 — intervention group
Group type: EXPERIMENTAL
Intervention: PenV 1.5 million IU thrice daily for 14 days
Number of subjects: 102
Study 16484823 — intervention group
Group type: COMPARATOR
Intervention: Both treatment groups
Number of subjects: 102
Study 15006038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with right frontal lobe lesions
Number of subjects: 49
Study 15006038 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with parietal lobe lesions
Number of subjects: 49
Study 15006038 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 49
Study 11345746 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (loading dose of 50 micrograms.kg‐1 and continuous infusion of 0.5 microgram.kg‐1.min‐1)
Number of subjects: 24
Study 11345746 — intervention group
Group type: COMPARATOR
Intervention: Control (dopamine and nitroglycerine administered)
Number of subjects: 24
Study 9152283 — intervention group
Group type: EXPERIMENTAL
Intervention: Playtex nipple unit
Number of subjects: 48
Study 9152283 — intervention group
Group type: COMPARATOR
Intervention: Gerber NUK nipple
Number of subjects: 48
Study 9152283 — intervention group
Group type: COMPARATOR
Intervention: Gerber Newborn nipple
Number of subjects: 48
Study 9152283 — intervention group
Group type: COMPARATOR
Intervention: Evenflo nipple
Number of subjects: 48
Study 8239591 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline plus rifampin (200 mg of doxycycline plus 600 mg of rifampin once daily for 6 weeks)
Number of subjects: 61
Study 8239591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin (400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks)
Number of subjects: 61
Study 8239591 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline plus rifampin
Number of subjects: 61
Study 8239591 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin plus rifampin
Number of subjects: 61
Study 3326117 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 0
Study 3326117 — intervention group
Group type: COMPARATOR
Intervention: 5 mg nitrazepam
Number of subjects: 0
Study 30382354 — intervention group
Group type: EXPERIMENTAL
Intervention: Betahistine
Number of subjects: 51
Study 30382354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27444427 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BiT (Buried in Treasures)
Number of subjects: 300
Study 27444427 — intervention group
Group type: COMPARATOR
Intervention: Group CBT (Cognitive Behavioral Therapy)
Number of subjects: 300
Study 27444427 — intervention group
Group type: EXPERIMENTAL
Intervention: Group BiT
Number of subjects: 300
Study 27444427 — intervention group
Group type: COMPARATOR
Intervention: Group CBT
Number of subjects: 300
Study 25039282 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CP (bortezomib 1.6 mg/m², rituximab 375 mg/m², cyclophosphamide 1000 mg/m², prednisone 100 mg)
Number of subjects: 55
Study 25039282 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CAP (bortezomib, rituximab, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone)
Number of subjects: 55
Study 22200806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (60 mg over 4 h in 500 ml of normal saline) administered monthly for 6 months
Number of subjects: 87
Study 22200806 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 87
Study 19879973 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chenodeoxycholate (CDC) 500 mg or 1000 mg, given for 4 days
Number of subjects: 44
Study 19879973 — intervention group
Group type: EXPERIMENTAL
Intervention: Colesevelam (1.875 g, twice daily)
Number of subjects: 44
Study 19879973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 18052925 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil meal (31 g of mixed fat and 9 g of fish oil)
Number of subjects: 25
Study 18052925 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil meal (40 g of mixed fat)
Number of subjects: 25
Study 12587957 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-targeted tablet-20
Number of subjects: 15
Study 12587957 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon-targeted tablet-30
Number of subjects: 15
Study 12587957 — intervention group
Group type: COMPARATOR
Intervention: Immediate release capsules
Number of subjects: 15
Study 9598887 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 1 mg/kg/day for 6 months
Number of subjects: 25
Study 9598887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7753719 — intervention group
Group type: EXPERIMENTAL
Intervention: Written only format
Number of subjects: 113
Study 7753719 — intervention group
Group type: EXPERIMENTAL
Intervention: Written and verbal format
Number of subjects: 113
Study 3140561 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 59
Study 3140561 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 6017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Double layer leucocyte agglutination method
Number of subjects: 0
Study 6017282 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific agglutination at 37°
Number of subjects: 0
Study 31279680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model for 18-month mortality after left-sided pancreatectomy
Number of subjects: 54
Study 31279680 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model validation
Number of subjects: 54
Study 29129174 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration oxygen therapy (delivered via Hudson mask at 8 L/min, without regard to Spo2)
Number of subjects: 22
Study 29129174 — intervention group
Group type: COMPARATOR
Intervention: Titrated oxygen therapy (oxygen delivered via nasal prongs to achieve peripheral oxygen saturation [Spo2] of 88‐92%)
Number of subjects: 22
Study 25741028 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous simulation training (n=10)
Number of subjects: 22
Study 25741028 — intervention group
Group type: COMPARATOR
Intervention: No previous training (n=12)
Number of subjects: 22
Study 23179204 — intervention group
Group type: EXPERIMENTAL
Intervention: C→H (cold to hot)
Number of subjects: 9
Study 23179204 — intervention group
Group type: EXPERIMENTAL
Intervention: H→C (hot to cold)
Number of subjects: 9
Study 21470671 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial access
Number of subjects: 7021
Study 21470671 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 7021
Study 19232907 — intervention group
Group type: EXPERIMENTAL
Intervention: FX06
Number of subjects: 234
Study 19232907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 17013922 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil (150-300 mg/day)
Number of subjects: 405
Study 17013922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 17013922 — intervention group
Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 405
Study 15233676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.i.d.
Number of subjects: 53
Study 15233676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 12 mg b.i.d.
Number of subjects: 53
Study 15233676 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 15233676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod (both doses)
Number of subjects: 53
Study 11094181 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal tension glaucoma (NTG)
Number of subjects: 79
Study 11094181 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open-angle glaucoma (POAG)
Number of subjects: 79
Study 11094181 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular hypertension (OH)
Number of subjects: 79
Study 11094181 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 79
Study 9296407 — intervention group
Group type: EXPERIMENTAL
Intervention: 12.5 mg I.V. dolasetron
Number of subjects: 620
Study 9296407 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg I.V. dolasetron
Number of subjects: 620
Study 9296407 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg I.V. dolasetron
Number of subjects: 620
Study 9296407 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg I.V. dolasetron
Number of subjects: 620
Study 9296407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 8363066 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study 8363066 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 100
Study 31781732 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Functional Exercise (HIFE) Program, 5 sessions per 2-week period for 4 months (total 40 sessions)
Number of subjects: 81
Study 30361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (hemoglobin A1c <6.0%)
Number of subjects: 10251
Study 30361335 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control for glycemic control)
Number of subjects: 10251
Study 30361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control (systolic BP <120 mm Hg)
Number of subjects: 10251
Study 30361335 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control for BP control)
Number of subjects: 10251
Study 30361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 10251
Study 30361335 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control for fenofibrate)
Number of subjects: 10251
Study 30361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 10251
Study 30361335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP control
Number of subjects: 10251
Study 27538108 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin needling plus silicone gel (Group A)
Number of subjects: 20
Study 27538108 — intervention group
Group type: COMPARATOR
Intervention: Skin needling (Control for Group A)
Number of subjects: 20
Study 27538108 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone gel plus skin needling (Group B)
Number of subjects: 20
Study 27538108 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel (Control for Group B)
Number of subjects: 20
Study 25066510 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-defined delirium
Number of subjects: 2197
Study 25066510 — intervention group
Group type: EXPERIMENTAL
Intervention: Study-defined subsyndromal delirium
Number of subjects: 2197
Study 25066510 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of delirium
Number of subjects: 2197
Study 25066510 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-specific prevalence of subsyndromal delirium
Number of subjects: 2197
Study 22070630 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway Unique
Number of subjects: 50
Study 22070630 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway Supreme
Number of subjects: 50
Study 19880501 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg orally, days 1 to 28 plus adriamycin and dexamethasone
Number of subjects: 556
Study 19880501 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide 50 mg daily (maintenance)
Number of subjects: 556
Study 17675321 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nebulised rhDNase
Number of subjects: 121
Study 17675321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 17675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall asthma score
Number of subjects: 121
Study 17675321 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation and bronchodilator treatments
Number of subjects: 121
Study 17142512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted influenza vaccine-trivalent
Number of subjects: 1616
Study 12576620 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment for chancroid
Number of subjects: 0
Study 12576620 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose regimens for H ducreyi infection
Number of subjects: 0
Study 11020674 — intervention group
Group type: EXPERIMENTAL
Intervention: Hoffmann reflex intervention
Number of subjects: 0
Study 8678100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2032
Study 8678100 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 2032
Study 8678100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime high-dose
Number of subjects: 2032
Study 1345436 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-EEG
Number of subjects: 115
Study 1345436 — intervention group
Group type: COMPARATOR
Intervention: Conventional EEG
Number of subjects: 115
Study 4008115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen + 300 mg theophylline
Number of subjects: 12
Study 4008115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen + 600 mg theophylline
Number of subjects: 12
Study 4008115 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ketotifen
Number of subjects: 12
Study 4008115 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg theophylline
Number of subjects: 12
Study 4008115 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg theophylline
Number of subjects: 12
Study 4008115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30690785 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 48
Study 30690785 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 48
Study 29474361 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented whey product
Number of subjects: 0
Study 29474361 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 25986540 — intervention group
Group type: EXPERIMENTAL
Intervention: Liverpool Care Pathway for the Dying Patient
Number of subjects: 19
Study 25986540 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 19
Study 24283778 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycopyrronium + Indacaterol (QVA149)
Number of subjects: 0
Study 24283778 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 0
Study 24283778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24283778 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrronium
Number of subjects: 0
Study 24283778 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol
Number of subjects: 0
Study 22946072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy‐based guided self‐management intervention adapted for Maori
Number of subjects: 16
Study 22946072 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study 20142594 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational session plus a CD‐ROM (n = 108)
Number of subjects: 213
Study 20142594 — intervention group
Group type: COMPARATOR
Intervention: Brief educational session with a health educator (n = 105)
Number of subjects: 213
Study 17377957 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 73
Study 17377957 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 73
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of knee flexion
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee flexion
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of knee extension
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee extension
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee flexion (interobserver)
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of knee flexion (interobserver)
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual assessment of knee extension (interobserver)
Number of subjects: 30
Study 15754228 — intervention group
Group type: EXPERIMENTAL
Intervention: Goniometric assessment of knee extension (interobserver)
Number of subjects: 30
Study 12005116 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) 0.25% and 0.5% patch test
Number of subjects: 0
Study 12005116 — intervention group
Group type: COMPARATOR
Intervention: Sodium lauryl sulphate (SLS) patch test
Number of subjects: 0
Study 10459543 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 2g
Number of subjects: 491
Study 10459543 — intervention group
Group type: EXPERIMENTAL
Intervention: MMF 3g
Number of subjects: 491
Study 10459543 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 491
Study 10459543 — intervention group
Group type: COMPARATOR
Intervention: MMF 2g vs PLA
Number of subjects: 491
Study 10459543 — intervention group
Group type: COMPARATOR
Intervention: MMF 3g vs PLA
Number of subjects: 491
Study 10459543 — intervention group
Group type: EXPERIMENTAL
Intervention: PLA, MMF 2g, MMF 3g
Number of subjects: 491
Study 7822659 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisone tapered over 8 days with intramuscular placebo
Number of subjects: 26
Study 7822659 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone sodium acetate and oral placebo
Number of subjects: 26
Study 2120986 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol-320 (32 g iodine)
Number of subjects: 200
Study 2120986 — intervention group
Group type: COMPARATOR
Intervention: iohexol-300 (45 g iodine)
Number of subjects: 200
Study 646497 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (Group A: 18 patients, Group C: 6 patients)
Number of subjects: 103
Study 646497 — intervention group
Group type: COMPARATOR
Intervention: Standard nonoperative measures (Group B: 61 patients) and early operation (Group D: 18 patients)
Number of subjects: 103
Study 646497 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal lavage (Group A and C)
Number of subjects: 103
Study 31937355 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-Spirit intervention
Number of subjects: 42
Study 31937355 — intervention group
Group type: COMPARATOR
Intervention: Active control group (VR-training with standard games)
Number of subjects: 42
Study 30649973 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (P + C)
Number of subjects: 0
Study 30649973 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab (P)
Number of subjects: 0
Study 29070849 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab-containing therapies
Number of subjects: 100
Study 25736286 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-HD video system
Number of subjects: 18
Study 25736286 — intervention group
Group type: COMPARATOR
Intervention: 2D-HD video system
Number of subjects: 18
Study 23574571 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-wrinkle cream containing retinol, hyaluronic acid, and dihydroxymethylchromone
Number of subjects: 87
Study 23574571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 21059877 — intervention group
Group type: EXPERIMENTAL
Intervention: RME followed by TPA therapy plus extraction of deciduous canines (RME/TPA/EC group, 40 subjects)
Number of subjects: 120
Study 21059877 — intervention group
Group type: EXPERIMENTAL
Intervention: TPA therapy plus extraction of deciduous canines (TPA/EC group, 25 subjects)
Number of subjects: 120
Study 21059877 — intervention group
Group type: EXPERIMENTAL
Intervention: Extraction of deciduous canines (EC group, 25 subjects)
Number of subjects: 120
Study 21059877 — intervention group
Group type: COMPARATOR
Intervention: No orthodontic treatment (Control group, CG, 30 subjects)
Number of subjects: 120
Study 19935017 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 20551
Study 19935017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20551
Study 17076946 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral polyethylene glycol (PEG)
Number of subjects: 36
Study 17076946 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (NaP)
Number of subjects: 36
Study 14571072 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention conducted by trained teachers using ad hoc developed materials.
Number of subjects: 4233
Study 14571072 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 4233
Study 10880165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ademetionine for four weeks
Number of subjects: 110